{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:56Z","timestamp":1786118936215,"version":"build-2736575974"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>To discuss updated guidelines for the provision of contraception to adolescents, review several contraceptive methods that have entered the market in recent years, and summarize insights from the literature that can assist clinicians in providing accurate, destigmatized contraceptive counseling to patients of all sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The 2024 United States Selected Practice Recommendations (US SPR) and United States Medical Eligibility for Contraceptive Use (US MEC) guidelines include changes to recommendations for contraception use in persons with various health conditions, and new advice for management of implant-associated breakthrough bleeding, pain control for intrauterine device (IUD) insertions, and counseling for patients who take testosterone. Subcutaneous Depo-Provera usage increased during the COVID-19 pandemic, and multiple studies demonstrate favorable patient experiences with it. Annovera, Miudella, Opill, Phexxi, Slynd, and Twirla are newer contraceptives which have distinct features that may make them attractive options for some patients. Contraception-related weight changes continue to be an active area of research. With the Food and Drug Administration (FDA) recommending broader BMI inclusion criteria, providers can expect more information about safety and efficacy of new contraceptives in individuals across the weight spectrum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001463","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T09:18:50Z","timestamp":1743671930000},"page":"318-324","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Contraception updates for adolescents"],"prefix":"10.1097","volume":"37","author":[{"given":"Anna","family":"Carleen","sequence":"first","affiliation":[{"name":"Nationwide Children's Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Ebersole","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital"},{"name":"The Ohio State University College of Medicine, Department of Pediatrics, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"R1-20250819","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jadohealth.2018.05.017","article-title":"Changing patterns of contraceptive use and the decline in rates of pregnancy and birth among U.S. adolescents, 2007-2014","volume":"63","author":"Lindberg","year":"2018","journal-title":"J Adolesc Health"},{"key":"R2-20250819","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/AOG.0000000000004659","article-title":"Patient-centered contraceptive counseling: ACOG Committee Statement Number 1","volume":"139","year":"2022","journal-title":"Obstet Gynecol"},{"key":"R3-20250819","doi-asserted-by":"crossref","first-page":"110723","DOI":"10.1016\/j.contraception.2024.110723","article-title":"Pandemic changes in U.S. contraceptive use: national survey estimates reveal significant differences by demographic subgroups","volume":"142","author":"Axinn","year":"2025","journal-title":"Contraception"},{"key":"R4-20250819","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12978-021-01139-2","article-title":"Women in larger bodies\u2019 experiences with contraception: a scoping review","volume":"18","author":"Boyce","year":"2021","journal-title":"Reprod Health"},{"key":"R5-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U. S. Medical Eligibility Criteria for contraceptive use, 2024","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"R6-20250819","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7303a1","article-title":"U. S. Selected Practice Recommendations for contraceptive use, 2024","volume":"73","author":"Curtis","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"R8-20250819","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/13625187.2015.1023893","article-title":"The relationship between unplanned pregnancy and maternal body mass index 2009-2012","volume":"20","author":"McKeating","year":"2015","journal-title":"Eur J Contracept Reprod Healthcare"},{"key":"R9-20250819","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpag.2016.02.007","article-title":"Gynecologic and obstetric consequences of obesity in adolescent girls","volume":"30","author":"Elizondo-Montemayor","year":"2017","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R10-20250819","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.contraception.2017.12.012","article-title":"The emerging role of obesity in short-acting hormonal contraceptive effectiveness","volume":"97","author":"Edelman","year":"2018","journal-title":"Contraception"},{"key":"R11-20250819","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"key":"R12-20250819","doi-asserted-by":"crossref","first-page":"110725","DOI":"10.1016\/j.contraception.2024.110725","article-title":"Society of Family Planning Committee Statement: contraception and body weight","volume":"141","author":"Zwayne","year":"2025","journal-title":"Contraception"},{"key":"R13-20250819","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jpag.2020.11.003","article-title":"Rates of intrauterine device expulsion among adolescents and young women","volume":"34","author":"Keenahan","year":"2021","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R14-20250819","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.contraception.2016.10.010","article-title":"Combined hormonal contraceptive (CHC) use among obese women and contraceptive effectiveness: a systematic review","volume":"95","author":"Dragoman","year":"2017","journal-title":"Contraception"},{"key":"R15-20250819","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajog.2012.04.022","article-title":"Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women","volume":"207","author":"Westhoff","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20250819","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.3390\/pharmacy8030156","article-title":"Long-lasting, patient-controlled, procedure-free contraception: a review of Annovera with a pharmacist perspective","volume":"8","author":"Virro","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"R17-20250819","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/AOG.0b013e318259565a","article-title":"Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women","volume":"120","author":"Xu","year":"2012","journal-title":"Obstet Gynecol"},{"key":"R18-20250819","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.contraception.2016.02.003","article-title":"The safety of subcutaneously administered depot medroxyprogesterone acetate (104\u200amg\/0.65\u200amL): a systematic review","volume":"94","author":"Dragoman","year":"2016","journal-title":"Contraception"},{"key":"R19-20250819","doi-asserted-by":"crossref","first-page":"110474","DOI":"10.1016\/j.contraception.2024.110474","article-title":"Emergency contraception for individuals weighing 80\u200akg or greater: a randomized trial of 30\u200amg ulipristal acetate and 1.5\u200amg or 30\u200amg levonorgestrel","volume":"137","author":"Edelman","year":"2024","journal-title":"Contraception"},{"key":"R20-20250819","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmjsrh-2024-202401","article-title":"Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial","volume":"51","author":"Edelman","year":"2025","journal-title":"BMJ Sex Reprod Health"},{"key":"R21-20250819","doi-asserted-by":"crossref","first-page":"326","DOI":"10.14740\/jocmr3792","article-title":"Prevalence of documented excessive weight gain among adolescent girls and young women using depot medroxyprogesterone acetate","volume":"11","author":"Jirakittidul","year":"2019","journal-title":"J Clin Med Res"},{"key":"R22-20250819","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/AOG.0000000000005712","article-title":"Body mass index changes among adolescents and young adults using the etonogestrel contraceptive implant","volume":"144","author":"Wernick","year":"2024","journal-title":"Obstet Gynecol"},{"key":"R24-20250819","doi-asserted-by":"crossref","first-page":"739","DOI":"10.15585\/mmwr.mm7020a2","article-title":"Update to U.S. selected practice recommendations for contraceptive use: self-administration of subcutaneous depot medroxyprogesterone acetate","volume":"70","author":"Curtis","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R26-20250819","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/psrh.12278","article-title":"Patient experiences switching from in-clinic to self-administration of injectable contraception in two Western US states","volume":"56","author":"Newmark","year":"2024","journal-title":"Perspect Sex Reprod Health"},{"key":"R27-20250819","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jpag.2023.06.005","article-title":"A pilot study of adolescent and young adult experience with subcutaneous depot medroxyprogesterone acetate","volume":"36","author":"Wernick","year":"2023","journal-title":"J Pediatr Adolesc Gynecol"},{"key":"R28-20250819","first-page":"618","article-title":"Segesterone acetate and ethinyl estradiol vaginal ring (Annovera) for contraception","volume":"101","author":"Lee","year":"2020","journal-title":"Am Fam Physician"},{"key":"R29-20250819","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1080\/17425247.2020.1764529","article-title":"A technology evaluation of Annovera: a segesterone acetate and ethinyl estradiol vaginal ring used to prevent pregnancy for up to one year","volume":"17","author":"Micks","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"key":"R30-20250819","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2020.05.004","article-title":"Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate","volume":"102","author":"Chen","year":"2020","journal-title":"Contraception"},{"key":"R31-20250819","doi-asserted-by":"crossref","first-page":"110771","DOI":"10.1016\/j.contraception.2024.110771","article-title":"Three-year efficacy, safety, and tolerability outcomes from a phase 3 study of a low-dose copper intrauterine device","volume":"143","author":"Creinin","year":"2024","journal-title":"Contraception"},{"key":"R33-20250819","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13669-021-00321-4","article-title":"New contraception update - Annovera, Phexxi, Slynd, and Twirla","volume":"11","author":"Baker","year":"2022","journal-title":"Curr Obstet Gynecol Rep"},{"key":"R34-20250819","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/13625187.2022.2164186","article-title":"The drospirenone (DRSP)-only pill: clinical implications in the daily use","volume":"28","author":"Kubba","year":"2023","journal-title":"Eur J Contracept Reprod Healthcare"},{"key":"R35-20250819","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jadohealth.2024.09.004","article-title":"Use of continuous oral drospirenone for menstrual suppression in adolescents","volume":"76","author":"Garbo","year":"2025","journal-title":"J Adolesc Health"},{"key":"R36-20250819","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajog.2014.09.014","article-title":"Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women","volume":"212","author":"Kaunitz","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R37-20250819","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"key":"R38-20250819","first-page":"628","article-title":"Lactic acid, citric acid, and potassium bitartrate (Phexxi) vaginal gel for contraception","volume":"103","author":"Steinberg","year":"2021","journal-title":"Am Fam Physician"},{"key":"R39-20250819","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/17512433.2022.2100347","article-title":"Lactic acid, citric acid, and potassium bitartrate nonhormonal prescription vaginal pH modulator (VPM) gel for the prevention of pregnancy","volume":"15","author":"Su","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R40-20250819","doi-asserted-by":"crossref","first-page":"110729","DOI":"10.1016\/j.contraception.2024.110729","article-title":"Retail availability of over-the-counter birth control pills at Texas pharmacies: results from a mystery caller study","volume":"142","author":"Wagner","year":"2025","journal-title":"Contraception"},{"key":"R41-20250819","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.whi.2017.11.006","article-title":"Interest in over-the-counter access to a progestin-only pill among women in the United States","volume":"28","author":"Grindlay","year":"2018","journal-title":"Womens Health Issues"},{"key":"R42-20250819","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2024.16474","article-title":"Over-the-counter oral contraceptives","volume":"332","author":"Grossman","year":"2024","journal-title":"JAMA"},{"key":"R43-20250819","doi-asserted-by":"crossref","first-page":"EVIDoa2400209","DOI":"10.1056\/EVIDoa2400209","article-title":"A proof-of-concept study of ulipristal acetate for early medication abortion","volume":"4","author":"Winikoff","year":"2025","journal-title":"NEJM Evid"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:11:15Z","timestamp":1786036275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MOP.0000000000001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001463","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}